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Abstract
Metformin is a widely prescribed drug used to treat type-2 diabetes, although recent studies
show it has wide ranging effects to treat other diseases. Animal and retrospective human
studies indicate that Metformin treatment is neuroprotective in Parkinson’s Disease (PD),
although the neuroprotective mechanism is unknown, numerous studies suggest the bene-
ficial effects on glucose homeostasis may be through AMPK activation. In this study we
tested whether or not AMPK activation in dopamine neurons was required for the neuropro-
tective effects of Metformin in PD. We generated transgenic mice in which AMPK activity in
dopamine neurons was ablated by removing AMPK beta 1 and beta 2 subunits from dopa-
mine transporter expressing neurons. These AMPKWT and KOmice were then chronically
exposed to Metformin in the drinking water then exposed to MPTP, the mouse model of PD.
Chronic Metformin treatment significantly attenuated the MPTP-induced loss of Tyrosine
Hydroxylase (TH) neuronal number and volume and TH protein concentration in the nigros-
triatal pathway. Additionally, Metformin treatment prevented the MPTP-induced elevation of
the DOPAC:DA ratio regardless of genotype. Metformin also prevented MPTP induced glio-
sis in the Substantia Nigra. These neuroprotective actions were independent of genotype
and occurred in both AMPKWT and AMPK KOmice. Overall, our studies suggest that Met-
formin’s neuroprotective effects are not due to AMPK activation in dopaminergic neurons
and that more research is required to determine how metformin acts to restrict the develop-
ment of PD.
Introduction
Parkinson’s Disease (PD) is the second most common neurodegenerative disease affecting an
estimated 4.1 to 4.6 million people worldwide in 2005, a number projected to double by the
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year 2030 [1]. Symptoms including tremor, postural instability and bradykinesia are due to a
reduction of dopamine in the dopaminergic nigrostriatal pathway in the brain. The dopamine
cell bodies are located in the substantia nigra (SN) and project to the striatum. PD is considered
idiopathic however many risk factors occur to increase incidence rates such as genetic factors,
pesticide exposure and recently several studies have shown a greater incidence in patients who
have diabetes [2–4]. Intriguingly, there is a correlation between the incidence of diabetes pre-
ceding PD development in individuals [5], indicating that glucose intolerance may be a precipi-
tating factor in the development of PD. Indeed, this is true in other neurological diseases where
individuals with Type 2 Diabetes (T2D) are at risk of developing mild cognitive impairment,
dementia or Alzheimers [6, 7]. If glucose intolerance is an early event or precipitating factor
in neurological conditions, then current therapeutic approaches to treat diabetes may offer
insights into the pathogenesis of neurological disease, such as PD. In support of this concept,
retrospective epidemiological study showed that Metformin-inclusive sulfonylurea therapy
reduced the risk of PD occurrence in patients with T2D in a Taiwanese population [8].
Metformin is a buigiunide analogue commonly used for the treatment of T2D and is gener-
ally well tolerated. By lowering blood glucose, IGF-1 and insulin signalling, Metformin creates
an environment that is similar to calorie restriction (CR) and as such many beneficial effects of
CR can be reproduced by chronic Metformin treatment. Metformin has been shown to extend
median survival by 40% in C. elegans, whilst also prolonging youthful locomotion in a dose-
dependent manner [9]. In mice Metformin produced approximately a 6% lifespan extension,
which was also accompanied by improved locomotor performance [10]. Indeed, in a human
study patients with T2D with Metformin monotherapy had a longer survival than matched
non-diabetic controls [11]. These studies collectively imply not only enhanced lifespan but also
healthspan with Metformin treatment. Metformin treatment also reduces the incidence of
many age related diseases by reducing cancer incidence [12], stroke risk [13], enhancing neuro-
genesis [14] as well as the traditional lowering of blood glucose. As CR is beneficial for PD [15]
and T2D [16], Metformin has the potential to treat both disease states.
Previous studies show that Metformin is neuroprotective in PD. In vitro, treatment with
Metformin reduced the neurotoxicity associated with alpha synuclein overexpression [17]. In a
Drosophila model of PD, Metformin treatment alleviated dopaminergic dysfunction and mito-
chondrial abnormalities [18]. Metformin chronically administered to mice reduces oxidative
stress, dopaminergic degeneration and motor abnormalities associated with MPTP (a mouse
model for PD) administration [19]. Hence, Metformin treatment has a protective effect in PD.
As Metformin has been deemed safe with minimal side effects and is known to rapidly cross
the blood brain barrier and disperse into various brain regions [20], it is an ideal therapeutic
for the treatment of PD. Recently, a mechanism of action for howMetformin suppresses gluco-
neogenesis has been discovered [21], however, how Metformin is neuroprotective is still
unknown. For example, after Metformin treatment the transcription factor SKN/Nrf2 is acti-
vated, ultimately increasing the expression of anti-oxidant genes to protect against oxidative
damage [9]. Metformin has also been shown to inhibit mTOR to enhance mitochondrial func-
tion [22, 23]. Metformin can also activate AMPK by inhibiting complex I of the ETC [24]. This
results in an increased AMP/ATP ratio and the subsequent activation of AMPK. AMPK acts to
increase mitochondrial biogenesis [25] and as patients with PD have impaired mitochondrial
function, suggesting that AMPK activation in dopamine neurons may be responsible for Met-
formin’s protective actions.
Peripheral activation of AMPK has been shown to be protective in PD. In cells overexpres-
sing alpha synuclein AMPK becomes activated to restrict cell death [17]. In a Drosophila
model of PD, loss of AMPK activity exacerbated neuronal loss and its associated phenotypes
[18]. Resveratrol, an AMPK activator is neuroprotective in a rodent model of PD [26]. In
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response to MPTP AMPK is phosphorylated and inhibition of AMPK by Compound C
enhanced MPTP-induced cell death [27]. However, it is unknown whether AMPK activation
in dopaminergic neurons is causative or correlative in the pathogenesis of PD. Many studies
have highlighted the beneficial effects of peripheral AMPK activators in PD [26, 28, 29] how-
ever, these neuroprotective actions could be due to indirect actions and may not involve
AMPK directly in dopamine neurons or could be due to an overall enhanced peripheral
profile.
As both Metformin treatment and AMPK activation protect against PD, we hypothesised
that Metformin would activate AMPK in dopaminergic neurons to prevent degeneration. We
aimed to determine if Metformin’s neuroprotective effects can be attributed to the activation of
AMPK in the SN dopamine neurons.
Material and Methods
Animals
All experiments were conducted in accordance with Monash University Animal Ethics Com-
mittee guidelines. The experiments in the study were specifically approved the Monash Animal
Research Platform Animal Ethic Committee (MARP/2012/042). Male mice were maintained
under standard laboratory conditions with free access to standard chow and water. Environ-
mental enrichment consisting of tissues and cardboard boxes cut to fit the cages was provided
in every cage. Mice were weighed and monitored daily. No mice died prior to the endpoint.
Due to the use of MPTP early termination was designated if suffering was observed or if body
weight fell below 70% of initial weight. All efforts were made to minimise suffering and isoflur-
ane was used at end of experiment. Temperature was maintained at 23°C with a 12 hour light/
dark cycle. Mice were 8–10 weeks old and group housed.
To generate mice with a selective deletion for AMPKβ1 & β2 only in DAT-expressing neu-
rons, we crossed Dat-Cre knock-in mice from Jax Lab Lab [Stock number 006660; B6.SJL-
Slc6a3<tm1.1(cre)bkmn>/j] with AMPK beta 1 (β1) and beta 2 (β2) floxed mice [30]. The
resultant offspring (Dat-Cre;Ampk beta 1fl/fl;Ampk beta 2fl/fl designated AMPK KO or Ampk
beta 1fl/fl;Ampk beta 2fl/fl designated AMPKWT) were used as experimental mice. Experimental
validation of mice was performed previously [31].
Experimental Design
Mice were randomly allocated to be treated with water or water containing Metformin
(100mg/kg/day) for the duration of the experiment (27 days). Metformin was given in water to
maintain constant levels of Metformin in the bloodstream and sustained activation of AMPK
as opposed to a single dose which is cleared rapidly from the system. Previous literature in
stroke models using 100mg/kg/day of Metformin showed increased AMPK activation in the
brain with this dose [32]. On days 20 and 21 mice received an injection of either saline or
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30mg/kg dissolved in saline). Mice
were deeply anaesthetised using isoflurane and were culled on day 27 and either perfused for
immunohistochemical analysis or fresh tissue collection for western blot and HPLC analysis.
Immunohistochemistry
All mice were deeply anaesthetized with isoflurane then perfused with 0.05M PBS followed by
4% Paraformaldehyde (PFA) to fix the tissue. Brains were stored in PFA overnight then trans-
ferred to 30% sucrose solution. Every fifth coronal section (30μm) was collected and stored in
cryoprotectant (30% Ethylene Glycol, 20% Glycerol in 0.1M PB) at -20°C. The sections were
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washed thoroughly with 0.1M PB and endogenous peroxidase activity was blocked with 1%
H2O2 in 0.1M PB for 15 minutes and washed again. The tissue was blocked with 4% normal
horse serum and 0.3% Triton X-100 in 0.1M PB for one hour and then blocked again with Affi-
niPure Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch, 1:200) to prevent non-specific
binding due to mouse tissue being stained with mouse antibodies. The tissue was then incu-
bated with the primary antibody, in this case anti-TH (mouse, 1:5000, Milipore) and anti-IBA1
(rabbit, 1:1000, Wako) or anti-GFAP (rabbit, 1:1000, DAKO) for 24 hours at 4°C. After the
incubation the sections were thoroughly washed and incubated with the fluorescent secondary
antibodies Goat anti-mouse IgG (H+L) AlexaFluor 488 (1:400, Invitrogen) and Goat anti-
rabbit IgG (H+L) AlexaFluor 594 (1:400, Invitrogen) for 90 minutes at room temperature.
The tissue was subsequently washed, mounted onto slides and cover-slipped using anti-fade
mounting media.
Stereological analysis of cell number and volume
We used design-based stereology to quantify the number of microglia (IBA1 stain), astrocytes
(GFAP stain) and the number and volume of dopamine neurons (TH stain) in the Substantia
Nigra. Using the StereoInvestigator software (MicroBrightField, Williston, VT, USA) we ana-
lysed cell number (optical fractionator probe) and cell volume (nucleator probe). To visualise
the cells we used a Zeiss microscope with a motorised stage and a MicroFibre digital camera
connected to the computer.
Analysis of blood chemistry
Trunk blood from deeply anesthetised decapitated mice was collected into EDTA tubes pre-
treated with pefabloc (SC Roche Applied Science, Mannheim, Germany) to achieve a concen-
tration of 1mg/mL. The blood was centrifuged and the plasma was acidified with HCl (final
concentration 0.05N). Plasma metabolites were measured following kit instructions. Active
Ghrelin or Des-Acyl Ghrelin Enzyme-Linked Immunoassay Kits (Mitsubishi Chemical Medi-
cine, Tokyo, Japan), NEFA (Wako Life Sciences; CA, USA), Triglycerides (Roche/Hitachi;
Indianopolis, USA), Corticosterone (Abnova; CA, USA) and Blood glucose (Sigma; Missouri,
USA). Plasma insulin concentration was determine through an in-house ELISA assay.
Western Blot
Fresh tissue was collected of the SN and Striatum and snap frozen in liquid nitrogen. Tissue
was then sonicated in RIPA buffer (50mM Tris, 150mMNaCl, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1% Triton X-100) containing a protease inhibitor (Sigma), then centrifuged (10,000
rpm, 10 minutes, 4°C) to remove cell debris and the supernatant was collected. The protein
concentration was measured using a BCA kit (Pierce, Rockford, IL, USA) according to kit
instructions. The samples concentrations were then standardised and the supernatants were
mixed with Laemmli’s buffer and boiled for 5 minutes. Samples were loaded onto 10% acryl-
amide gels and separated by SDS polyacrylamide gel electrophoresis, the separated proteins
were then transferred from the gel to a PVDF membrane (Biorad). The blots were bocked for 1
hour in Tris-Buffered Saline Solution containing 0.1% Tween-20 (TBST) and 5% Bovine
Serum Albumin (BSA). The membrane were incubated overnight at 4°C in TBST with 5% BSA
containing one of the following antibodies: anti-TH (1:1000, Milipore), anti-beta actin (1:1000,
Abcam), anti-AMPKα (1:1000, Cell signalling) or anti-pAMPK (1:1000, Cell Signaling). Blots
were visualised using chemiluminescence (ECL, Amersham) and levels of proteins were
detected using ImageLab Software, version 4.1, Biorad.
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High Performance Liquid Chromatography (HPLC)
We performed HPLC to identify, separate and quantify both dopamine and DOPAC concen-
trations within the striatum. Striatal tissue was rapidly dissected and snap frozen (approxi-
mately -70°C). The samples were then sonicated in 0.4mL cold 0.1M perchloric acid
containing the internal standard. After centrifugation DA, DOPAC and the internal standard
in the supernatant were extracted on alumina at pH 8.4, eluted in 0.1M perchloric acid, sepa-
rated by reverse-phase HPLC and detected using electrochemical detection. The concentration
of dopamine and DOPAC were calculated in reference to the internal and external standards.
The Lowry method was used to determine the protein content of each sample from the centri-
fuged pellet. The concentrations of dopamine and DOPAC are expressed as ng/mg of protein
present (mean ± SEM).
Oral Glucose Tolerance Test (oGTT) and Insulin Tolerance Test (ITT)
Mice were fasted for 4 hours prior to first blood measurement. We used short term fasting as
this better studies insulin action in the physiological context [33]. Blood glucose was measured
with ACCU-CHEK Active (Roche DiagnosticsGnH, Tokyo, Japan) and then a 25% D-glucose
solution (1.5g/kg) was given by oral gavage and measurements were taken at time points 15,
30, 60 and 90 minutes after bolus. The mice were allowed to recover for 1 week until the ITT
was performed. For the ITT the same protocol was followed except the mice were injected i.p
1U/kg insulin.
Statistical Analysis
All data are represented as Mean ± Standard Error of the Mean (SEM). Two-Way ANOVA
with a Bonferroni post hoc test was used to determine statistical significance between treat-
ments. P<0.05 was considered statistically significant.
Results
Physiological characterisation of AMPK KOmice
DAT AMPKWT and KO were exposed to either normal drinking water or water with Metfor-
min and then injected with MPTP to induce degeneration in Substantia Nigra (SN) dopamine
neurons, as a mouse model for PD (raw data available; S1–S11 Files). There were no genotype
differences in body weight (Fig 1A, 1C & 1D), blood glucose (Fig 1E & 1F) or insulin levels (Fig
1G & 1H). Because Metformin is known to promote insulin sensitivity [34] we determined if
Metformin in the drinking water affected clearance of glucose during an oral Glucose Toler-
ance Test (oGTT) and Insulin Tolerance Test (ITT). In AMPKWTmice there was no differ-
ence between mice chronically exposed to Metformin compared to tap water alone in both
oGTT (Fig 1I), Area under the curve (Fig 1J) and the ITT (Fig 1M). However, in AMPK KO
mice Metformin significantly increased glucose clearance (Fig 1K) at the 15-minute time-
point, however the area under the curve showed no significant differences between water and
Metformin treatment (Fig 1L). There was no difference in the ITT (Fig 1N). This indicates that
AMPK activation in dopamine neurons does not promote peripheral glucose clearance during
an oGTT or ITT.
Plasma analysis showed a significant main effect of MPTP to increase Triglycerides (Fig 2A
& 2B), Non-Esterified Fatty Acids (NEFA) (Fig 2C & 2D) and corticosterone (Fig 2E & 2F) lev-
els, which occurred with a concurrent reduction in body weight (Fig 1A) indicating the stress
placed on these mice. These hormones were measured to determine if metabolic feedback was
playing a role in the neuroprotective actions of Metformin. To confirm the inability of AMPK
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to become phosphorylated in the AMPK KOmice we performed protein analysis in the SN
and Striatum. In both the SN and striatum AMPKWTmice had an elevated pAMPK/AMPK
ratio after MPTP exposure (Fig 2I & 2K). AMPK KOmice exhibited no significant change in
the pAMPK/AMPK ratio in response to MPTP in either the SN (Fig 2J) or Striatum (Fig 2L)
Fig 1. BodyWeight and blood glucosemeasurements in AMPKWT and KOmice. A–D, throughout the
experiment there was no difference in body weight or volume of water consumed comparing genotype or
treatment. Arrows indicate MPTP injections. E–H, Plasma analysis of insulin and glucose levels in trunk
blood show no differences between genotype and treatment. During an oGTTMetformin treatment does not
alter glucose clearance in AMPKWT (I & J) or AMPK KOmice (K & L). Insulin sensitivity is not altered during
an ITT in AMPKWT (M) or KO (N) mice treated with Metformin. * = p<0.05. Data are represented as
mean ± SEM (n = 8–10, two-way ANOVA, p<0.05).
doi:10.1371/journal.pone.0159381.g001
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Fig 2. Metformin is neuroprotective in AMPKWT and KOmice. Plasma Triglycerides (A & B), NEFA (C &
D) and corticosterone (E & F) are elevated in response to MPTP. Representative Western Blot images of
pAMPK/AMPK in the SN (G) and Striatum (H). Protein analysis of the pAMPK/AMPK ratio showing no
elevation in response to MPTP in the SN (J) and Striatum (L) in AMPK KO but an elevation in both the SN
and Striatum of AMPKWTmice (I & K). Representative images of TH levels in the SN (M) and Striatum (N).
In the SN there is a significant reduction in TH levels in both AMPKWT (O) and KO (P) in response to MPTP.
In the StriatumMetformin elicits a neuroprotective effect in MPTP treated AMPKWT (Q) and KO (R) mice.
MPTP reduced dopamine and DOPAC in both AMPKWT (S & T) and AMPK KO (V &W) mice. Metformin
reduced the elevation of the DOPAC:DA ratio in MPTP treated mice compared to water alone, in AMPKWT
and KOmice (U & X) a, significant compared to water/saline treated mice and b, significant compared to
water/MPTP treated mice. Data are represented as mean ± SEM (n = 6–9, two-way ANOVA, p<0.05).
doi:10.1371/journal.pone.0159381.g002
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implying an inability to be phosphorylated in response to a toxic insult as a protective mecha-
nism, as observed previously [31].
Metformin prevents MPTP-induced nigrostriatal damage independent of
genotype
MPTP significantly reduced Tyrosine Hydroxylase (TH, a dopamine marker) protein expres-
sion, as measured by western blot in both the SN and Striatum in both AMPKWT and KO
mice (Fig 2M–2R) an effect that was attenuated by metformin in both AMPKWT and KO
mice in the Striatum (Fig 2Q & 2R) but not in the SN (Fig 2O & 2P). In support of this data,
HPLC analysis of dopamine (Fig 2S & 2V) and DOPAC (Fig 2T & 2W) in the striatum revealed
a significant overall reduction with MPTP administration in both AMPKWT and KO mice
with no effect of Metformin treatment. However, Metformin treatment prevented the increase
in the DOPAC:DA ratio observed after MPTP in both AMPKWT and KOmice (Fig 2U &
2X). These results indicate that Metformin has site-specific protective effects in the Striatum.
MPTP administration significantly reduced the number and volume of TH positive SN neu-
rons in both AMPKWT and KOmice. Metformin attenuated the loss of neurons in AMPK
WT (Fig 3A) and KOmice (Fig 3B) and also prevented a reduction in cell volume in both geno-
types (Fig 3C & 3D), with the majority of the beneficial effect occurring in smaller cells between
1000–2000μm3 (Fig 3E & 3F). This protective effect was also accompanied by reduced gliosis.
MPTP administration significantly elevated microglia (IBA1+ cells) and astrocytes (GFAP+
cells) in the SN, which indicates greater cellular damage in that region. MPTP significantly ele-
vated IBA1 (Fig 3G–3I) and GFAP (Fig 3J–3L) in both AMPKWT and KOmice. Metformin
treatment blunted the gliosis response to MPTP in both AMPKWT and KO mice, indicating a
protective effect of Metformin regardless of genotype (Fig 3H–3K).
Together, the TH cell number, cell volume and protein expression in the Striatum data indi-
cate that Metformin elicits a protective effect in an MPTP mouse model of PD independent of
AMPK action in the dopaminergic neurons.
Discussion
Metformin has been a major therapeutic option for the treatment of T2D since 1958 in the UK
and 1995 in the USA. It is the most commonly prescribed drug in the treatment of T2D in clin-
ical use. Recently, the use of Metformin to treat diseases other than T2D has increased. Metfor-
min prevents the development of renal [35], hepatic [36], cardiac [37, 38] and neurological
conditions [39]. Indeed, Alzheimers Disease (AD) is closely associated with impaired insulin
signalling and glucose metabolism and is often referred to as “type 3 diabetes” [40]. There is a
correlation between insulin resistance and an elevated risk for AD development [41] and stud-
ies conducted in obese leptin-resistant mice showed that Metformin attenuated AD-like neuro-
pathology and biological markers [39]. These studies collectively imply that Metformin has the
ability to negate any elevated risk for AD development in the susceptible patients who already
have T2D. However, it should be noted in a population based study following>7000 people
taking Metformin (or other antidiabetic drugs) there was no elevated risk for developing AD
[42].
Metformin has recently been shown to have neuroprotective effects in PD patients. A recent
epidemiological study illustrated that the incident Parkinson’s risk in patients with pre-existing
diabetes treated with sulfonylureas increased by 57%, which was prevented when co-medicated
with Metformin [8]. We show that Metformin treatment is neuroprotective by attenuating
dopamine number and volume loss, reducing gliosis, restricting TH protein loss and enhancing
dopamine turnover in the striatum. This study highlights the neuroprotective potential of
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Fig 3. Metformin preserves cell number and volume after MPTP exposure, independent of genotype.
Stereological quantification of TH levels in the SN shows a protective effect of Metformin after MPTP
exposure in both AMPKWT (A) and KO (B) mice. Overall cell volume shows a significant reduction after
MPTP exposure in water treatment but not with Metformin treatment in AMPKWT (C) and KO (D). When TH
cells were separated and plotted based on volume distribution, mice treated with MPTP and Metformin had a
significant effect on smaller volume (1000–2000μm3) cells compared to those not treated with Metformin in
both AMPKWT (E) and KO (F) mice.G, Representative image showing MPTP induced microglial activation
in the SN (green = TH, red = IBA1). Stereological quantification of IBA1 (H & I) and GFAP (J & K) showing
increased numbers after MPTP with a significant protective effect of Metformin in both AMPKWT and KO. L,
Representative images showing MPTP induced astrocytic activation in the SN (green = TH and red = GFAP).
a, significant compared to Water/saline treated mice and b, significant compared to Water/MPTP treated
mice. * = p<0.05. Data are represented as mean ± SEM (n = 7–10, two-way ANOVA, p<0.05).
doi:10.1371/journal.pone.0159381.g003
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Metformin to reduce the risk for developing PD and although the evidence for neuroprotection
is clear in animal and cell-based models [19, 43, 44], the mechanism underlying this effect is
not.
One of Metformin’s mechanisms of action in terms of insulin sensitivity is to promote
AMPK activation as shown in cells [24] and tissues such as the liver [24] and muscle [45]. In
our studies we clearly demonstrate that Metformin reduces degeneration of the nigrostriatal
system in a mouse model of PD, however these protective effects are not dependent on AMPK
activation in dopamine neurons. In this study we used a mouse model where AMPKβ1 and
AMPKβ2 were successfully deleted in DAT expressing neurons. AMPK is composed of three
subunits: alpha, beta and gamma. The alpha subunit plays a catalytic role whereas beta and
gamma are regulatory. We chose the beta subunit as deletion of both AMPKβ1 and AMPKβ2
in muscle ablated AMPK phosphorylation [30]. A potential limitation in this model is the use
of transgenic mice. There is potential that these controls (CRE negative, floxed positive) react
differently to Metformin and/or MPTP as the floxed allele has been carried from conception.
We recently used this novel mouse line to show that ghrelin increases AMPK in dopamine neu-
rons, which is responsible for the neuroprotective actions of calorie restriction in PD [31].
These results and the impaired striatal AMPK phosphorylation in AMPK KOmice in this
study highlights the validity of using this mouse model to explore whether Metformin requires
AMPK activation to prevent degeneration in a mouse model of PD.
AMPK activation attenuates dopaminergic dysfunction in a drosophila model of PD [18].
Other activators of AMPK including Resveratrol [26] and ghrelin [31, 46] are neuroprotective
in vivo. Overexpression of alpha synuclein in cells (as a model of PD) activates AMPK in order
to restrict cell death [17]. Although AMPK activation is neuroprotective in PD and Metformin
induces direct protective effects through AMPK in other disease states such stroke [47], our
studies show that Metformin doesn’t activate AMPK in dopamine neurons to prevent degener-
ation in a mouse model of PD. However, this model was using mice which selectively had
AMPK activity removed in dopaminergic neurons hence AMPK could elicit neuroprotective
actions within cells external to the neurons. As there was a significant reduction in gliosis
with Metformin treatment in both AMPKWT and KOmice after MPTP treatment there is
potential for AMPK activity in microglia / astrocytes to elicit neuroprotective actions. Indeed,
in vitro studies indicate that AMPK activation within microglia suppresses pro-inflammatory
responses [48]. As inflammation is a key hallmark in PD [49], AMPK activation within micro-
glia may be responsible for the neuroprotective actions of Metformin, although this theory
requires experimental proof.
There are many other potential mechanisms through which Metformin can act. For exam-
ple Metformin inhibits apoptosis in neuronal cortical cells [43], prevents oxidative stress-
related cellular death [50] and plays an inhibitory role on inflammatory transcription factor
NF-kB [51]. In mice exposed to Metformin there was reduced superoxide leakage in the mito-
chondria, indicating greater efficiency of mitochondrial complexes [10]. As complex I activity
is diminished in PD patients [52] this enhanced mitochondrial efficiency coupled with reduced
oxidative stress could be responsible for the neuroprotective actions of Metformin. Metformin
also activates Sirtuins (SIRTs) and PGC-1α. SIRTs are responsible for a variety of cellular pro-
cesses including enhancing mitochondrial function, cellular metabolism, gluconeogenesis as
well as aging [53]. There are increased levels and activity of SIRTs in the livers of Metformin
treated mice [54]. SIRT activation improves mitochondrial function and extends lifespan [55].
Indeed, lifespan is increased in mice overexpressing SIRT1 [56] and decreased in SIRT1 KO
[57]. Another potential target that Metformin could act through is PGC-1α, a transcriptional
regulator involved in mitochondrial biogenesis. Metformin has been shown to increase PGC-
1α protein expression in the liver [58] and skeletal muscle [59]. PGC-1α deficient mice are
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more susceptible to MPTP-induced dopaminergic neuronal loss [60]. In mice, overexpression
of PARIS, which represses the expression of PGC-1α, results in selective degeneration of sub-
stantia nigra dopaminergic neurons [61]. In humans polymorphisms of PGC-1α are associated
with early onset PD [62]. Collectively, these studies show that Metformin’s neuroprotective
actions could be due to many other agents that enhance mitochondrial function independent
of AMPK activation. It is important to note that AMPK interacts with SIRT1 and PGC-1α.
AMPK enhances SIRT1 activity, enhances the downstream target PGC-1α and increases mito-
chondrial biogenesis [25]. Also, AMPK can both activate and be activated by SIRT1 [63],
creating a complex interplay between AMPK, SIRT1 and PGC-1α. Future research should
determine if SIRT1 and PGC-1α play a role in the neuroprotective actions of Metformin.
Metformin can increase circulating levels of the gut hormone GLP-1 to help control blood
glucose levels [64]. GLP1 also has receptors on SN dopaminergic neurons and prevents neuro-
degeneration in a mouse model of PD [65, 66]. This elevation could be responsible for the pro-
tective actions of Metformin and raises the possibility that the neuroprotective actions of
metformin are secondary to changes in peripheral metabolism.
Many studies have shown the protective actions of Metformin in different disease states
however, the neuroprotective mechanism of Metformin in PD remains unknown. It potentially
exhibits disease and dose specific actions in different tissues. Although it is possible that Met-
formin is neuroprotective in other disease states such as stroke and Alzheimer’s Disease via the
actions of AMPK, we show that in a mouse model of PDMetformin’s neuroprotective actions
are independent to AMPK activation in dopaminergic neurons. Further research is required to
determine the exact neuroprotective mechanism of action of Metformin however, some poten-
tial options involve indirect effects on metabolism including elevated GLP-1 secretion or direct
effects of SIRT1 and PGC-1α in SN dopamine neurons.
Supporting Information
S1 File. Data for Corticiosterone assay.
(XLSX)
S2 File. Data for oral glucose tolerance tests.
(XLSX)
S3 File. Data for HPLC analysis.
(XLSX)
S4 File. Body weight data for 1 cohort of metformin treated mice.
(XLSX)
S5 File. Data for blood glucose.
(XLSX)
S6 File. Data for body weight for another cohort of mice.
(XLSX)
S7 File. Data for plasma insulin assay.
(XLS)
S8 File. Data for stereology.
(XLSX)
S9 File. Data for western blot analysis.
(XLSX)
Metformin Prevents Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons
PLOS ONE | DOI:10.1371/journal.pone.0159381 July 28, 2016 11 / 15
S10 File. Data for plasma NEFA analysis.
(XLSX)
S11 File. Data for plasma TG analysis.
(XLSX)
Author Contributions
Conceived and designed the experiments: JAB ZBA. Performed the experiments: JAB VVS MD
ML JE. Analyzed the data: JAB JE. Contributed reagents/materials/analysis tools: BEK JSD.
Wrote the paper: JAB ZBA.
References
1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected
number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology.
2007; 68(5):384–6. Epub 2006/11/04. doi: 10.1212/01.wnl.0000247740.47667.03 PMID: 17082464.
2. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2
diabetes and the risk of Parkinson's disease. Diabetes care. 2008; 31(10):2003–5. Epub 2008/07/05.
doi: 10.2337/dc08-0688 PMID: 18599528; PubMed Central PMCID: PMCPmc2551644.
3. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's dis-
ease. Diabetes Care. 2007; 30(4):842–7. PMID: 17251276.
4. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. The International jour-
nal of neuroscience. 1993; 69(1–4):125–30. Epub 1993/03/01. PMID: 8082998.
5. D'Amelio M, Ragonese P, Callari G, Di Benedetto N, Palmeri B, Terruso V, et al. Diabetes preceding
Parkinson's disease onset. A case-control study. Parkinsonism Relat Disord. 2009; 15(9):660–4. Epub
2009/04/10. doi: 10.1016/j.parkreldis.2009.02.013 PMID: 19356970.
6. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes & metabolism.
2006; 32(5 Pt 1):403–14. Epub 2006/11/18. PMID: 17110895.
7. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related
pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002; 51(4):1256–62. Epub 2002/03/28. PMID:
11916953.
8. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea ther-
apy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population
cohort. Parkinsonism Relat Disord. 2012; 18(6):753–8. Epub 2012/04/14. doi: 10.1016/j.parkreldis.
2012.03.010 PMID: 22498320.
9. Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response
to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010; 5(1):e8758. Epub
2010/01/22. doi: 10.1371/journal.pone.0008758 PMID: 20090912; PubMed Central PMCID:
PMCPmc2807458.
10. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. Met-
formin improves healthspan and lifespan in mice. Nature communications. 2013; 4:2192. Epub 2013/
08/01. doi: 10.1038/ncomms3192 PMID: 23900241; PubMed Central PMCID: PMCPmc3736576.
11. Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, et al. Can people
with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with
metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, obesity &
metabolism. 2014; 16(11):1165–73. Epub 2014/07/22. doi: 10.1111/dom.12354 PMID: 25041462.
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer
in diabetic patients. BMJ (Clinical research ed). 2005; 330(7503):1304–5. Epub 2005/04/26. doi: 10.
1136/bmj.38415.708634.F7 PMID: 15849206; PubMed Central PMCID: PMCPmc558205.
13. Cheng YY, Leu HB, Chen TJ, Chen CL, Kuo CH, Lee SD, et al. Metformin-inclusive therapy reduces
the risk of stroke in patients with diabetes: a 4-year follow-up study. Journal of stroke and cerebrovascu-
lar diseases: the official journal of National Stroke Association. 2014; 23(2):e99–105. Epub 2013/10/15.
doi: 10.1016/j.jstrokecerebrovasdis.2013.09.001 PMID: 24119365.
14. Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-
CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell stem cell. 2012;
11(1):23–35. Epub 2012/07/10. doi: 10.1016/j.stem.2012.03.016 PMID: 22770240.
Metformin Prevents Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons
PLOS ONE | DOI:10.1371/journal.pone.0159381 July 28, 2016 12 / 15
15. DuanW, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral out-
come and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci
Res. 1999; 57(2):195–206. PMID: 10398297.
16. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al. Reduction in weight and car-
diovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD
trial. Diabetes care. 2007; 30(6):1374–83. Epub 2007/03/17. doi: 10.2337/dc07-0048 PMID: 17363746;
PubMed Central PMCID: PMCPmc2665929.
17. Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, et al. The protec-
tive role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol Dis. 2014;
63:1–11. Epub 2013/11/26. doi: 10.1016/j.nbd.2013.11.002 PMID: 24269733.
18. Ng CH, Guan MS, Koh C, Ouyang X, Yu F, Tan EK, et al. AMP kinase activation mitigates dopaminer-
gic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J Neu-
rosci. 2012; 32(41):14311–7. Epub 2012/10/12. doi: 10.1523/JNEUROSCI.0499-12.2012 PMID:
23055502.
19. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-
induced Parkinson's disease in mice. Neuroscience. 2014; 277:747–54. Epub 2014/08/12. PMID:
25108167.
20. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the
HPLCmethod in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
Pharmacological reports: PR. 2010; 62(5):956–65. Epub 2010/11/26. PMID: 21098880.
21. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses
gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510
(7506):542–6. Epub 2014/05/23. doi: 10.1038/nature13270 PMID: 24847880; PubMed Central PMCID:
PMCPmc4074244.
22. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related dis-
ease. Nature. 2013; 493(7432):338–45. Epub 2013/01/18. doi: 10.1038/nature11861 PMID: 23325216;
PubMed Central PMCID: PMCPmc3687363.
23. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells. Cancer research. 2007; 67
(22):10804–12. Epub 2007/11/17. doi: 10.1158/0008-5472.can-07-2310 PMID: 18006825.
24. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in
mechanism of metformin action. J Clin Invest. 2001; 108(8):1167–74. Epub 2001/10/17. doi: 10.1172/
JCI13505 PMID: 11602624; PubMed Central PMCID: PMC209533.
25. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy
expenditure by modulating NAD+metabolism and SIRT1 activity. Nature. 2009; 458(7241):1056–60.
Epub 2009/03/06. nature07813 [pii] doi: 10.1038/nature07813 PMID: 19262508.
26. Jin F, WuQ, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkin-
son's disease in rats. Eur J Pharmacol. 2008; 600(1–3):78–82. Epub 2008/10/23. S0014-2999(08)
01024-8 [pii] doi: 10.1016/j.ejphar.2008.10.005 PMID: 18940189.
27. Choi JS, Park C, Jeong JW. AMP-activated protein kinase is activated in Parkinson's disease models
mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun. 2010; 391
(1):147–51. Epub 2009/11/12. doi: 10.1016/j.bbrc.2009.11.022 PMID: 19903456.
28. Horvath TL, Erion DM, Elsworth JD, Roth RH, Shulman GI, Andrews ZB. GPA protects the nigrostriatal
dopamine system by enhancing mitochondrial function. Neurobiol Dis. 2011; 43(1):152–62. doi: 10.
1016/j.nbd.2011.03.005 PMID: 21406233; PubMed Central PMCID: PMC3623269.
29. Bayliss JA, Andrews ZB. Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of
metabolic neuroprotection. Ther Adv Endocrinol Metab. 2013; 4(1):25–36. Epub 2013/03/22. doi: 10.
1177/2042018813479645 PMID: 23515333; PubMed Central PMCID: PMC3593299.
30. O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD, et al. AMP-activated
protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining
mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci U S A. 2011; 108
(38):16092–7. Epub 2011/09/08. doi: 10.1073/pnas.1105062108 PMID: 21896769; PubMed Central
PMCID: PMC3179037.
31. Bayliss JA, Lemus MB, Stark R, Santos VV, Thompson A, Rees DJ, et al. Ghrelin-AMPK Signaling
Mediates the Neuroprotective Effects of Calorie Restriction in Parkinson's Disease. J Neurosci. 2016;
36(10):3049–63. doi: 10.1523/JNEUROSCI.4373-15.2016 PMID: 26961958; PubMed Central PMCID:
PMC4783502.
32. Li J, Benashski SE, Venna VR, McCullough LD. Effects of metformin in experimental stroke. Stroke; a
journal of cerebral circulation. 2010; 41(11):2645–52. Epub 2010/09/18. doi: 10.1161/strokeaha.110.
589697 PMID: 20847317; PubMed Central PMCID: PMCPmc2994809.
Metformin Prevents Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons
PLOS ONE | DOI:10.1371/journal.pone.0159381 July 28, 2016 13 / 15
33. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, et al. Standard operating proce-
dures for describing and performing metabolic tests of glucose homeostasis in mice. Disease models &
mechanisms. 2010; 3(9–10):525–34. Epub 2010/08/18. doi: 10.1242/dmm.006239 PMID: 20713647;
PubMed Central PMCID: PMC2938392.
34. McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP. Metformin increases insulin
sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Australian
and New Zealand journal of medicine. 1991; 21(5):714–9. Epub 1991/10/01. PMID: 1759920.
35. Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carl-
ton, Vic). 2010; 15(4):412–8. Epub 2010/07/09. doi: 10.1111/j.1440-1797.2010.01328.x PMID:
20609092.
36. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the
management of NAFLD. Experimental diabetes research. 2012; 2012:716404. Epub 2011/12/24. doi:
10.1155/2012/716404 PMID: 22194737; PubMed Central PMCID: PMCPmc3238361.
37. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Cur-
rent opinion in lipidology. 2011; 22(6):445–53. Epub 2011/09/08. doi: 10.1097/MOL.
0b013e32834ae1a7 PMID: 21897229.
38. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, et al. Metformin protects the
ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Basic research in cardiology. 2008; 103(3):274–84. Epub 2007/12/15. doi: 10.1007/s00395-007-0691-
y PMID: 18080084.
39. Li J, Deng J, ShengW, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese,
leptin-resistant mice. Pharmacology, biochemistry, and behavior. 2012; 101(4):564–74. Epub 2012/03/
20. doi: 10.1016/j.pbb.2012.03.002 PMID: 22425595; PubMed Central PMCID: PMCPmc3327803.
40. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. Journal of dia-
betes science and technology. 2008; 2(6):1101–13. Epub 2009/11/04. PMID: 19885299; PubMed Cen-
tral PMCID: PMCPmc2769828.
41. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated
with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010; 75(9):764–70. Epub
2010/08/27. doi: 10.1212/WNL.0b013e3181eee25f PMID: 20739649.
42. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's dis-
ease: a population-based case-control study. Journal of the American Geriatrics Society. 2012; 60
(5):916–21. Epub 2012/03/31. doi: 10.1111/j.1532-5415.2012.03916.x PMID: 22458300.
43. El-Mir MY, Detaille D, G RV, Delgado-Esteban M, Guigas B, Attia S, et al. Neuroprotective role of antidi-
abetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci. 2008; 34
(1):77–87. Epub 2007/11/28. doi: 10.1007/s12031-007-9002-1 PMID: 18040888.
44. Adeyemi OO, Ishola IO, Adedeji HA. Novel action of metformin in the prevention of haloperidol-induced
catalepsy in mice: Potential in the treatment of Parkinson's disease? Progress in neuro-psychopharma-
cology & biological psychiatry. 2013. Epub 2014/02/12. doi: 10.1016/j.pnpbp.2013.10.014 PMID:
24513020.
45. Musi N, HirshmanMF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases
AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes.
2002; 51(7):2074–81. Epub 2002/06/28. PMID: 12086935.
46. Bayliss JA, Lemus M, Santos VV, Deo M, Elsworth J, Andrews ZB. Acylated but not des-acyl ghrelin is
neuroprotective in an MPTPmouse model of Parkinson's Disease. J Neurochem. 2016. doi: 10.1111/
jnc.13576 PMID: 26872221.
47. Jiang T, Yu JT, Zhu XC, Wang HF, Tan MS, Cao L, et al. Acute metformin preconditioning confers neu-
roprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. British
journal of pharmacology. 2014; 171(13):3146–57. Epub 2014/03/13. doi: 10.1111/bph.12655 PMID:
24611741; PubMed Central PMCID: PMCPmc4080970.
48. Lu DY, Tang CH, Chen YH, Wei IH. Berberine suppresses neuroinflammatory responses through
AMP-activated protein kinase activation in BV-2 microglia. Journal of cellular biochemistry. 2010; 110
(3):697–705. Epub 2010/06/01. doi: 10.1002/jcb.22580 PMID: 20512929.
49. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Par-
kinson's disease. Experimental & molecular medicine. 2006; 38(4):333–47. Epub 2006/09/06. doi: 10.
1038/emm.2006.40 PMID: 16953112.
50. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative
stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes research and clinical practice.
2011; 93(1):56–62. Epub 2010/12/15. doi: 10.1016/j.diabres.2010.11.030 PMID: 21146883.
51. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular
transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013; 110(3):972–7. Epub
Metformin Prevents Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons
PLOS ONE | DOI:10.1371/journal.pone.0159381 July 28, 2016 14 / 15
2013/01/02. doi: 10.1073/pnas.1221055110 PMID: 23277563; PubMed Central PMCID:
PMCPmc3549132.
52. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I defi-
ciency in Parkinson's disease. J Neurochem. 1990; 54(3):823–7. Epub 1990/03/01. PMID: 2154550.
53. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature.
2009; 460(7255):587–91. Epub 2009/07/31. doi: 10.1038/nature08197 PMID: 19641587; PubMed
Central PMCID: PMCPmc3727385.
54. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic
gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010; 205(1):97–106. Epub
2010/01/23. doi: 10.1677/joe-09-0345 PMID: 20093281.
55. Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, Abulwerdi G, et al. The SIRT1
activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell reports.
2014; 6(5):836–43. Epub 2014/03/04. doi: 10.1016/j.celrep.2014.01.031 PMID: 24582957; PubMed
Central PMCID: PMCPmc4010117.
56. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. SIRT1 transgenic mice show
phenotypes resembling calorie restriction. Aging cell. 2007; 6(6):759–67. Epub 2007/09/20. doi: 10.
1111/j.1474-9726.2007.00335.x PMID: 17877786.
57. Boily G, Seifert EL, Bevilacqua L, He XH, Sabourin G, Estey C, et al. SirT1 regulates energy metabo-
lism and response to caloric restriction in mice. PLoS One. 2008; 3(3):e1759. Epub 2008/03/13. doi:
10.1371/journal.pone.0001759 PMID: 18335035; PubMed Central PMCID: PMCPmc2258149.
58. Aatsinki SM, Buler M, Salomaki H, Koulu M, Pavek P, Hakkola J. Metformin induces PGC-1alpha
expression and selectively affects hepatic PGC-1alpha functions. British journal of pharmacology.
2014; 171(9):2351–63. Epub 2014/01/17. doi: 10.1111/bph.12585 PMID: 24428821; PubMed Central
PMCID: PMCPmc3997275.
59. SuwaM, Egashira T, Nakano H, Sasaki H, Kumagai S. Metformin increases the PGC-1alpha protein
and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. Journal
of applied physiology (Bethesda, Md: 1985). 2006; 101(6):1685–92. Epub 2006/08/12. doi: 10.1152/
japplphysiol.00255.2006 PMID: 16902066.
60. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, et al. Suppression of reactive oxygen spe-
cies and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006; 127(2):397–408.
PMID: 17055439.
61. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, et al. PARIS (ZNF746) repression of PGC-
1alpha contributes to neurodegeneration in Parkinson's disease. Cell. 2011; 144(5):689–702. Epub
2011/03/08. doi: 10.1016/j.cell.2011.02.010 PMID: 21376232; PubMed Central PMCID: PMC3063894.
62. Clark J, Reddy S, Zheng K, Betensky RA, Simon DK. Association of PGC-1alpha polymorphisms with
age of onset and risk of Parkinson's disease. BMCmedical genetics. 2011; 12:69. Epub 2011/05/21.
doi: 10.1186/1471-2350-12-69 PMID: 21595954; PubMed Central PMCID: PMCPmc3112073.
63. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for
AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;
15(5):675–90. Epub 2012/05/09. doi: 10.1016/j.cmet.2012.04.003 PMID: 22560220; PubMed Central
PMCID: PMCPmc3545644.
64. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-
induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011; 152
(12):4610–9. Epub 2011/10/06. doi: 10.1210/en.2011-1485 PMID: 21971158.
65. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al. Peptide hormone
exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery
in an animal model of Parkinson's disease. Journal of neuroscience research. 2008; 86(2):326–38.
Epub 2007/09/07. doi: 10.1002/jnr.21483 PMID: 17803225.
66. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation pre-
serves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkin-
sonism. Proc Natl Acad Sci U S A. 2009; 106(4):1285–90. Epub 2009/01/24. doi: 10.1073/pnas.
0806720106 PMID: 19164583; PubMed Central PMCID: PMCPmc2633544.
Metformin Prevents Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons
PLOS ONE | DOI:10.1371/journal.pone.0159381 July 28, 2016 15 / 15
